🔴 Gilead Sciences, Inc. is trading 3.6% down today following FDA acceptance of Yeztugo filing and positive Phase 3 HIV data

Gilead Sciences, Inc. is trading 3.6% down today at $46700.00, following recent announcements of the U.S. FDA's acceptance of its supplemental New Drug Application for Yeztugo (once-weekly oral HIV prevention) and positive Phase 3 data for a separate once-weekly HIV treatment regimen.

The stock's movement is seen as a reaction to these significant corporate developments, which previously fueled a rally of 4.04% on June 19.

Broader U.S. indices are trading mixed to slightly flat today, suggesting the move is stock-specific.